Algae are more than just Sushi

Algaetech
Algaetech

With an investment from Britain's Grovepoint, Kibbutz Ketura's Algatech sees endless uses for marine agriculture.

Visiting Kibbutz Ketura, 50 kilometers from Eilat and the home of Algatechnologies, which develops microalgae materials used in the cosmetic and pharmaceutical industry, CEO Hagai Stadler insists on personally introducing me to all of the company's employees. Chairman Ed Hofland - also chairman of the Aravah Power solar energy manufacturer, in which the Kibbutz is a partner - has been a member of Ketura since he arrived there as a volunteer from Holland in 1978, married an Israeli and settled down. Operations manager, Mike Harris, arrived in Israel that same year, from England, setting his roots in the kibbutz. When Yael Premen, HR Manager and Kibbutz member for the last four years describes how new Kibbutz members are accepted to the Kibbutz in order to “start working for us”, Stadler corrects her and says: “start working with us”.

The subtle semantic reflects the kibbutz atmosphere that they wish to maintain under the new owners, Britain's Grovepoint investment fund, which acquired control of the company (60%) early last year at a valuation of $50 million as a business investment. Indeed, the investment fund heads - Bradley Fried and Leon Blitz - British Jews of South African descent, have a connection to Israel, but they are first and foremost business people, as demonstrated in another investment of theirs - the acquisition of the French “Total” chain of gas stations operating in the UK. “Grovepoint acknowledged that Algatech has unrealized potential”, says Stadler who, beyond serving as CEO of Algatech, is also Grovepoint’s Israeli representative and, as such, he seeks out investments for it. “We found a distinctive technology and we saw that it was already operational. Beyond that, Bradley and Leon are men of values as well as being successful businesspeople. When we examined investments in Israel, we said that we want to find companies that have the potential of harnessing Israeli initiative toward adding value to the world’s shortage of resources, i.e. food and water. These are the worlds that we can relate to. We did not want just another start-up. We wanted a company that we could grow globally and we realized that Algatech was just that”.

Didn’t you consider investing, for example, in Aravah Power, in which the Kibbutz is a partner?

“We do not relate to that as much. In infrastructural companies, the profit margins can reach 15% and we are looking for profit margins of 30-40%. What we want to do is take a company, grow it and turn it into something stable. We are going toward a complex and difficult process and we do not want to compete with the Chinese”.

What do you mean?

“I really like the Asians, but our added value does not lie in mass production. We are not looking for “Omega 3”, but rather for that unique substance that has an added value. A product that is not easy to grow, on the one hand, but that has a market, on the other. The world is shifting toward natural materials, made of biological organisms, as compared to synthetic materials made of oil. The world has realized that nature does it better than man”.

How does that fit in with Grovepoint’s investment in gas stations?

In Israel, Grovepoint is looking for different things. Algatech brings with it outstanding capabilities and its professionalism, drill-down capacity and strategic viewpoint is something to be learned. The complexity of the operations here is the highest. We have here a long, difficult and highly detailed process. It requires accuracy and this kind of complexity interests us.

Give me an example of a company that is your model.

“Enzymotec, for example. It just completed a very good IPO, we think that this is the kind of company that we could follow.”

Do you have an IPO planned?

“No, we are currently focusing on Algatech’s future. We want to grow, not only organically, and we are also considering acquiring companies that will enable a good fit with Algatech and allow it to increase its product offering”.

What about dividends? After all, you are an investment company.

“I assume that the desire to enjoy the investment will come around, but right now, we want to grow. We do not have a window of time, it is not Apex. We do not have a stopwatch and we are here to see companies grow. One of Grovepoint’s investors is an 80-year old Jew, one of Britain’s richest, and he says: ‘I want to see a company for 40 years. After all, once you perform an exit, where will you invest the money? In another company like the one that you just sold?”

The Good and the Bad

Algatech was founded 15 years ago when a member of Kibbutz Ketura, Yoram Hoffman completed his doctoral studies with Prof. Sammy Boussiba, an algae specialist at Ben Gurion University. He still serves as an advisor to Algatech. Hoffman, now retired, identified the potential of algae, convinced the kibbutz to invest and, supported by the JCA, they established Algatech.

The main substance that the company extracts from algae cells is astaxanthin or, in short, Asta. It is among the best active antioxidants for man “500-1,000 times more active than Vitamin E”, as explained by Chamutal Krugliak, the company’s Chief Biologist. Just as important: “unlike other nutritional supplements, Asta does not cause damage when consumed in excess.” It is a substance that positively effects vision, strengthens the immune system, improves skin texture and protects it against radiation. In addition, being an antioxidant, it serves as an anti-aging agent for all physical systems.

Algatech’s Asta production process is fascinating. First, they grow the algae cells in pampering conditions or, as Operations Manager Harris says, “in a five-star hotel.” The algae cells flow through narrow pipes with water, while introducing CO2. The pipes are protected by shading curtains and all growth parameters are subject to 24-hour monitoring. But several days later, the pampering hotel transforms into a sweatshop for the algae cells, which are transferred to different pipes where they are forced to cope with high exposure to the sun and conditions of starvation. This torture requires the cells to protect themselves by secreting the asta, which is red.

“It’s the good and the bad”, Stadler describes the unique desert conditions. “The desert has the sun and no clouds; on the other hand, the desert doesn’t like to be meddled with. It isn’t easy to deal with nature and that is actually the challenge that the company faces. There’s always something happening here - one day there are floods, then there is a haze and then a heat wave. The Aravah is one of the most difficult locations, but when you realize that this difficult location bred a company that developed a breakthrough technology, you realize that there is hope and that the best technology emerges from these difficult locations, when people have to work to their limits.

When I ask about the difference between Algatech and the NBT algae factory near Eilat, belonging to a Japanese cosmetics and health product manufacturer, Algatech points to two differences: first, Algatech works with algae cells while NBT works with algae. Furthermore, they say, the Japanese algae strain is a specific strain used to produce beta-carotene, while theirs, haematococcus, is a different strain that they developed. “Saying algae”, says Stadler, “is like saying tree. There are tens and hundreds of thousands of algae strains and species. Each algae is unique in its own right, with qualities of its own”.

“Lucky there was no air raid”

Prior to Grovepoint’s involvement, Algatech was managed as a family business. Indeed, it did not report a deficit when it caught the eyes of the Britons, but it had not yet achieved stability. Since Grovepoint took over (60%) last year, it underwent a process to change its strategic focus, efficiency and control. “Since they arrived, our operations have become more professional”, confirms chairman Hofland. “It is evident at all levels: internally, in the market and in the results. Before this, we reached our glass ceiling and now we have moved up. We needed someone to push us. We may have had the vision, but we needed the money and the executive capacity. We were the ultimate acquisition for them: we were starting to get big, but we were not professionally managed. That was the time to step in”.

Since investing in Algatech, Grovepoint has invested tens of millions of shekels in the company and as it stands, one can cautiously say that the investment is fruitful. The company is growing, turnover is increasing and the factory is currently expanding at a cost of ~60M NIS, taking over the Kibbutz dairy farm, which still owns 20% of the Company and JCA, which retained similar holdings. “If you’d have asked anyone in the Kibbutz about the dairy farm disappearing”, Stadler describes the complexity of the partnership, “they would have thought you’re delusional. And yet, we did it”.

Recently, he adds, Algatech signed a cooperation agreement with Germany's Schott Corporation, which manufactures glass components for the pharma, chemical and solar industry. “They wanted to enter the algae world as partners in development and Algatech had become their main R&D activity”, says Stadler. “They will develop more effective pipes, whose radiation will be improved. As a result, we managed to increase our production by 10%. We place our efforts in the algae and they place theirs in the glass”.

Algatech is Grovepoint’s first investment in Israel. Grovepoint was founded four years ago and it manages billions of dollars in investments. “Just so you understand who these people are”, Stadler relates to his employers. “Brad’s son had a Bar Mitzvah in the midst of Operation Protective Edge. He wanted to have it in Israel and bring many people from overseas. I suggested that he think about it, but he was determined. He insisted that they celebrate in Israel. People came to the celebration and there was a missile interception during the event, but luckily there were no sirens sounded. That goes to show you what kind of people we are dealing with, people who have a real commitment to Israel”.

In his vision, Stadler sees Algatech as a farm for growing dozens of microalgae species, each of them applied to a different objective “encouraging metabolism, for example” - and the Aravah as the Silicon Valley of marine agriculture, which is currently “very primitive”. “The Aravah is not just about peppers”, he says. “Not that I have anything against peppers, but I believe that Israel should focus on niche agricultural fields, not simple ones; and not peppers that were grown in hothouses 20 years ago and can be imitated”.

“I truly hope that the Aravah picks up the gauntlet on all that is related to marine creature biotechnology. Thus far, only 5% of the algae were studied. This potential of providing people food through marine products is only just appearing. It is a super-attractive world and, when looking at the needs of the world, one must take advantage of the capabilities in Israel, like Prof. Boussiba’s research lab and the Lake and Sea Research Center. Israel has the proper marine agriculture potential and institutions, and there is no reason not to do it.”

Published by Globes [online], Israel business news - www.globes-online.com - on November 13, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Dr. Adi Tzoref-Lorenz credit: Jonathan Bloom "My research says I don't accept there is no answer"

The death of a cancer patient spurred Dr. Adi Tzoref-Lorenz into developing the OHI index, which allows the diagnosis of the HLH side effect from cancer immunotherapy, based on two blood tests.

Dr. R  credit: Jonathan Bloom Wounded in his tank, now R develops protection systems

"I was close to death, but it sharpened my awareness of the products we develop for the IDF."

Ella Kenan  credit: Yossi Cohen A fighter of fake news about Israel

Ella Kenan saw online denial of October 7 happening straightaway. "I realized we had 24 hours, or we were doomed"

Liron Horshi credit: Jonathan Bloom Wiz's talent manager nurtures $1b workforce

Wiz's $32 billion sale to Google was rooted in the cloud security product if offers but could not have been achieved without the quality of its employees built by human resources chief Liron Horshi.

Yoav Shoham  credit: Eyal Izhar Yoav Shoham: AI isn't too smart, it's too dumb

AI21 Labs founder and CEO Prof. Yoav Shoham talks to "Globes" about dubious doomsday predictions, what should really concern us, and what could make Israel a global AI leader.

Record public company profits  credit: Tali Bogdanovsky Profits peak, but reckoning awaits

In what may seem a paradox, profits grew in almost every sector on the Tel Aviv Stock Exchange last year, but the boom was largely fueled by government spending.

Insightec COO and general manager Eyal Zadicario credit: Ness Productions After 25 years of losses Insightec focuses on profit

Insightec COO and general manager Eyal Zadicario tells "Globes" about himself and the Israeli ultrasound company's long battle to change the medical world.

Amit Shaked credit: Tomer Lesher Driven to succeed but balancing ambition with wellbeing

At just 14, cybersecurity company Rubrik VP Amit Shaked began a B.Sc. in Computer Science and Math and mapped out his entire future, which included IDF service in the 8200 unit, and an inevitable huge startup exit.

Advs. Roy Keidar and Netanella Treistman credit: Nicky Westphal AI blind spot startups can no longer afford to ignore

How AI governance can assist startups and enhance their ability to succeed.

Dr. Ola Gutzeit  credit: Ketty Hakim The doctor breaking new ground in fertility

"We know nothing about the female reproductive system," says Dr. Ola Gutzeit of Rambam Hospital. She seeks to change that, and hence change IVF for the better.

Google CEO Sundar Pichai  crediit: Shutterstock Why Google is paying so much for Wiz

Lagging its competitors in cloud and AI, and facing challenges to its core advertising business, Google could be looking to spend its way out of trouble.

Donald Trump speaking on the deck of the USS Gerald R. Ford  at its launch in 2017 credit: Reuters/Jonathan Ernst Houthis between hammer and anvil

President Trump appears determined to end the Houthi threat to shipping, while Iran has abandoned the last active arm of its "axis of resistance."

Prof. Douglas Irwin  credit: Inbal Marmari "We will all be poorer"

Prof. Douglas Irwin, an expert on international trade, talks to "Globes" about the impact of President Trump's tariffs policy, and what Israel can do about it.

Rooftop solar panels credit: Shutterstock Does it pay for homes to install rooftop solar panels?

As the Israeli government steps up efforts to encourage homeowners to produce their own electricity from rooftop panels, "Globes" investigates the advantages and pitfalls.

Dop Elbit banner at London's Allianz HQ credit: Reuters PA Images Violence against Israeli defense cos in UK escalates

"The Sunday Times" has investigated Palestine Action, a radical left-wing group that targets Israeli defense companies, their subsidiaries, and corporations and banks with any connection to Israel.

UnitedHealth founder Richard Burke credit: Ken Easley UnitedHealth founder: US health system is broken

In an exclusive interview Richard Burke talks about the murder of the company's CEO, Donald Trump, his love for Israel, and investment in Israeli startup Korro AI.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018